Athira Pharma, Inc. (ATHA)
NASDAQ (CM) NASDAQ (CM) Primary 
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript
ATHA Energy expands uranium potential at Angilak
ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) revealed that a survey at its Angilak uranium project in Nunavut has expanded the known depth of uranium mineralization at the Lac 50 Deposit to over one kilometer. The survey also identified a new 25-kilometer conductive trend along the western margin of the Angikuni Basin, according to a statement from ATHA.
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct
Seattle-area biotech company Athira Pharma agreed to pay $4.
ATHA Energy identifies high-grade uranium mineralization in new outcrops at Angilak
ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) said it has uncovered numerous outcrops hosting high-grade uranium mineralization at Angilak in Nunavut. The surficial mapping program, centered around the Lac 50 Deposit, identified mineralized outcrops between the Lac 48, Lac 50, Lac 52, and Lac 54 trends, according to a statement from ATHA.
ATHA Energy reveals updated technical report for Angilak uranium project
ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) has unveiled its updated 2024 technical report for its 100%-owned Angilak uranium project in Nunavut. The third-party updated technical report establishes a baseline Exploration Target for the Lac 50 Deposit of 60.8–98.2 million pounds of U₃O₈ (uranium) with an average grade range of 0.37–0.48% U₃O₈.
ATHA Energy appoints seasoned experts to leadership team
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has announced the appointment of Erinn Broshko as a non-executive director and Rhéal Assié as chief financial officer, starting November 6. The company said Broshko, a seasoned executive and lawyer, brings more than 25 years of experience in law, business, and leadership, including roles as CEO and executive chairman in biotech and energy services.
ATHA Energy and Terra Uranium enter into strategic option agreements on key uranium projects
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced that it has entered into option agreement with Terra Uranium Ltd (ASX:T92) which allow the two companies to earn significant interest in each other's uranium exploration projects. ATHA has granted Terra Uranium an option to acquire up to 70% interest in its Spire and Horizon properties, together the Spire Horizon projects.
ATHA Energy CEO highlights 2024 growth priorities at TD Securities Nuclear Roundtable
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) CEO Troy Boisjoli highlighted the company's aggressive growth strategy and plans for the year ahead in a discussion at the TD Securities Annual Nuclear Fuel Cycle and Next Generation Nuclear Roundtable. ATHA, listed in April 2023, has rapidly expanded its uranium exploration portfolio.
ATHA Energy secures entire Lac 50 structural corridor at Angilak uranium project
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has expanded its Angilak Project in Nunavut by acquiring the entire Lac 50 structural corridor, along with an additional prospective parallel corridor. Both corridors are linked to the Snowbird Tectonic Zone, a significant crustal structure that extends from the Athabasca Basin to the Angikuni Basin.
Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring
Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
On Wednesday, Athira Pharma, Inc. ATHA stock is trading lower after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's disease (AD).
